Cadrenal Therapeutics, Inc. (CVKD)
After hours:
| Previous close | 1.2600 |
| Open | 1.2700 |
| Bid | 1.2200 x 2200 |
| Ask | 1.2500 x 1300 |
| Day's range | 1.2300 - 1.3300 |
| 52-week range | 1.2000 - 6.7500 |
| Volume | |
| Avg. volume | 329,875 |
| Market cap | 14.543M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, recognizes National Kidney Month throughout the month of March as it advances tecarfarin for a severely underserved subset of the overall kidney disease population.
- PR Newswire
Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, and other Cadrenal team members will ring the Nasdaq Stock Market closing bell on Wednesday, February 8, 2023.
- PR Newswire
Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, is available for one-on-one meetings at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis Times Square on February 6-8, 2023.
